Opipramol in the treatment of somatoform disorders

A total of 1183 patients with somatoform disorders (ICD;10) were treated wi th opipramol over 8 weeks in neurological-and psychiatric practices; The di agnostic classifications, the anamnestic data, adverse reactions and the th erapeutic outcome were evaluated and recorded in a standardized procedure. Despite a marked to severe initial symptomatology and pretreatment rates as high as 66% most patients (77%) showed an improvement of greater than or e qual to 2 in CGI-score after 8 weeks of treatment with opipramol. The respo nse rates in different subgroups of somatoform disorder ranged between 72,7 and 82,7%. The mean daily dosage of opipramol was 133 mg. Adverse reaction s were reported in 2,4% of the patients, 12 patients had to stop treatment with opipramol. After the end of the study 84% of the patients continued on opipramol. Our data confirm and extent results from past and recent studie s with opipramol.